{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_Display\ Name in Display Name (approximate match)
Status:
Investigational
Source:
INN:tenifatecan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Tenifatecan (also known as SN2310 or tocopherol succinate-SN38), camptothecin, is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan. It is known that SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Tenifatecan successfully completed phase I clinical trial in patients with advanced solid tumors. Achieve Life Sciences, the company that is developing this drug, are currently exploring options to out-license tenifatecan.
Status:
Investigational
Source:
USAN:LODOXAMIDE ETHYL [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Lodoxamide ethyl, diethyl N,N'-(2-chloro-5-cyano-m-phenylene) dioxamate, is an orally active candidate for the treatment of asthma and other allergic diseases. Lodoxamide ethyl prevents mast cell mediator release during allergic reactions in rats, guinea pigs, and monkeys at doses well below toxic levels. Lodoxamide ethyl does not interfere with antigen-antibody interaction, does not antagonize the effects of histamine or slow-reacting substance of anaphylaxis, and does not have direct antiinflammatory effects. Lodoxamide ethyl has been proven capable of preventing bronchospasm in humans when the subject was given 1, 3, or 10 mg of the drug orally prior to challenge with an antigen.
Status:
Excipient
Source:
1%w/w TOPICAL SHAMPOO
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:930522
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:731020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
FDA ORPHAN DRUG:761020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:655018
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/14/1239
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)